🔓
Sign in as a Member to unlock the full view of HALO. · Full hedge fund list, every line-item carveout, cabinet conflicts, and politicians-trading detail.
Become a Member$29.99/mo already a Member? Sign in →
HALO

Halozyme Therapeutics, Inc.

Sector: healthcareBiotechnologyNASDAQMarket Cap: $8.35B

Halozyme is a specialty pharma company focused on drug delivery and immuno-oncology with minimal direct government dependence but moderate regulatory exposure typical of biotech.

Next filing → your inbox
Govt Dependence
15/100
Regulatory Density
75/100
Lobbying Intensity
5/100
Political Signal
LOW

BusinessWhat HALO does

Halozyme develops proprietary drug delivery technologies (primarily hyaluronic acid-based) and manufactures biologics for partners. Revenue derives from royalties on partnered drugs, contract manufacturing services, and licensing fees. The company has limited direct Medicare/Medicaid exposure but operates in heavily regulated pharma development and manufacturing.

12 months past · 3 months futureHALO activity timeline

$135$97$60 DecJan '26FebMarAprMayJunJulAugSepOctNovDecJan '27Feb ↓ PAST — recorded activity ↑ FUTURE — scheduled markups · pending votes TODAY · Nov 17 $131.18 hi $61.63 lo $100.27 CONGRESS 20 INSIDERS 0 13F FUNDS 30 BILLS 30 Gilbert Ray Cisneros (D) · Sale (Partial) · 2026-09-29Gilbert Ray Cisneros (D) · Purchase · 2026-03-09 D.E. Shaw & Co. · + $160M · 2026-06-30Two Sigma Investments · holds $129M · 2026-06-30D.E. Shaw & Co. · + $123M · 2026-03-31D.E. Shaw & Co. · - $106M · 2025-12-31Two Sigma Investments · + $102M · 2026-03-31Citadel Advisors · + $97M · 2026-06-30Renaissance Technologies · + $66M · 2026-09-30AQR Capital Management · OPENED $65M · 2026-03-31AQR Capital Management · - $61M · 2026-06-30Point72 Asset Management · + $61M · 2026-03-31Point72 Asset Management · + $61M · 2026-06-30Two Sigma Investments · - $48M · 2025-12-31Renaissance Technologies · + $47M · 2026-03-31Citadel Advisors · + $46M · 2025-12-31Renaissance Technologies · - $38M · 2025-12-31Bridgewater Associates · + $38M · 2025-12-31Renaissance Technologies · - $38M · 2026-06-30Bridgewater Associates · - $36M · 2026-06-30Citadel Advisors · - $33M · 2026-06-30 HR.227 · enacted · 2026-10-20HR.184 · reported · 2026-09-15HR.178 · reported · 2026-01-08HR.210 · committee · 2026-05-20HR.109 · committee · 2025-12-19 MARKUP · Senate Veterans' Affairs · 2026-11-18MARKUP · Senate Finance · 2026-11-18MARKUP · Senate Health, Education, Labor, and Pensions · 2026-11-18MARKUP · Senate Budget · 2026-11-18MARKUP · Senate Veterans' Affairs · 2026-11-18
Congress
buy sell
Insider · Form 4
open-market buy
Hedge fund · 13F
opened + added − trimmed closed holds
Bills
past action (this ticker) upcoming markup (sector) ★ carveout (this ticker)
249 trading days · 2 congressional trades shown · 0 insider buys · 19 13F filings · 5 past bill actions · 5 upcoming markups

Lifetime Government AwardsHALO federal contracts

HALO doesn't hold direct federal contracts.

Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.

Smart Money · 13F HoldingsHedge funds holding HALO

$672.3M
Total HALO held by tracked 13F funds
11
Funds with HALO positions
+1
Funds opened this quarter
D.E. Shaw & Co. $160M +8% 2026-06-30
Two Sigma Investments $129M holds 2026-06-30
Citadel Advisors $97M +453% 2026-06-30
Renaissance Technologies $66M +25% 1 overlap 2026-09-30
AQR Capital Management $61M -23% 2026-06-30
Point72 Asset Management $61M +451% 2026-06-30
Bridgewater Associates $36M -9% 2026-06-30
Citadel Advisors $33M -98% 2026-06-30
3 more 13F positions tracked · quarterly delta charts available in member dashboard

Politicians Trading HALOMembers of Congress with recent HALO positions

1 politicians traded HALO across 4 disclosed transactions totaling $32K (last 730 days). Greed score = composite of trade frequency, volume & recency across the politician's entire history (not just HALO). 0-30 LOW · 30-60 MID · 60+ HIGH.

Congressional TradesWho in Congress is trading HALO

2026-09-29 Gilbert Ray Cisneros D-California · house Sale (Partial) $1,001 - $15,000
2026-03-09 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
2025-03-24 Gilbert Ray Cisneros D-California · house sale $1,001 - $15,000
2025-03-24 Gilbert Ray Cisneros D-California · house Sale $1,001 - $15,000
2024-09-09 Josh Gottheimer D-New Jersey · house sale $1,001 - $15,000
2024-09-09 Josh Gottheimer D-New Jersey · house Sale $1,001 - $15,000
2023-07-12 Daniel S. Goldman D-New York · house sale $15,001 - $50,000
2023-07-12 Daniel S. Goldman D-New York · house Sale $15,001 - $50,000
2022-12-06 Josh Gottheimer D-New Jersey · house sale $1,001 - $15,000
2022-12-06 Josh Gottheimer D-New Jersey · house Sale $1,001 - $15,000
2022-08-05 Josh Gottheimer D-New Jersey · house sale $1,001 - $15,000
2022-08-05 Josh Gottheimer D-New Jersey · house Sale $1,001 - $15,000
20+ trades on file · most recent 2026-10-12

Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock

Stock awards & option exercises

2
stock awards · $250K market value
12
option exercises · $4.4M
2026-10-01 Daly James M Director AWARD 1,169 sh $125K
2026-09-01 Appelhans Dannielle Director AWARD 1,161 sh $125K
For HALO, executives receive stock primarily as compensation rather than via open-market purchases — typical for established large-cap firms.

Bills Affecting HALOLive legislation impacting this stock

Political ProfileWhere HALO sits in Washington

Halozyme has minimal lobbying footprint, no named legislative wins/losses, and no clear congressional alignment. Stock moves primarily on clinical/commercial biotech events, not policy.

Regulatory ExposureThreats & opportunities

Regulatory threats

  • FDA manufacturing compliance tightening
  • drug pricing pressure from CMS

Regulatory opportunities

  • Orphan drug incentives
  • accelerated approval pathways for oncology
Member intelligence layer

Live signals + predictions for HALO — for Founders

The free page above gives you the public record. Members see the real-time intelligence layer on top of it:

Become a Founder · $29.99/mo Locked rate forever · cancel anytime

Frequently AskedAbout HALO & political exposure

Does Halozyme Therapeutics, Inc. (HALO) hold federal contracts?
No direct prime contracts reported in USASpending.gov for Halozyme Therapeutics, Inc.. Companies in the semiconductor and AI hardware sectors often sell to the federal government via prime contractors and cloud resellers (Microsoft Azure, AWS, Lockheed Martin systems integration) rather than as direct primes.
Has Congress traded HALO stock?
20 congressional trades by 4 unique members of Congress, most recently on 2026-09-29. See the Congressional Trading panel for politician-by-politician breakdown.
What is HALO political risk profile?
Government dependence: 15/100. Lobbying intensity: 5/100. Political signal: low.
How does GovGreed track HALO political activity?
GovGreed integrates STOCK Act congressional trade disclosures, FEC contributions, OGE executive-branch disclosures, USASpending federal contracts, Senate LDA lobbying filings, and SEC Form 4 corporate insider trades into a single queryable graph. HALO data is updated daily from these official federal sources.